As more trials are run using devices that collect objective measurements of biomarkers devices like "double blind" and "placebo" will become less necessary.
Proper use of objective data will speed drug development and discovery.
The actigraph will do more than monitor sleep patterns. Please remember this is a Parkenson's disease trial and tremors are part of the disease. The actigraph will also be able to show if the PD tremors are reduced. That is something that the animal models showed IIRC.
So, the actigraph will be multi faceted in its application.
News 
Market Data 
Discover 
